An update from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK plc announced the purchase of 587,100 of its own ordinary shares as part of its ongoing share buyback program. The shares were acquired at prices ranging from 1,482.00p to 1,516.00p, with a volume-weighted average price of 1,490.87p. This transaction, executed through Citigroup Global Markets Limited, adds to the 14,037,087 shares already repurchased since February 2025, reflecting GSK’s strategy to enhance shareholder value and optimize its capital structure.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a leading global healthcare company operating in the pharmaceutical industry. It focuses on the development and production of vaccines, medicines, and consumer healthcare products, aiming to improve the quality of human life by enabling people to do more, feel better, and live longer.
YTD Price Performance: 11.53%
Average Trading Volume: 8,787,427
Technical Sentiment Signal: Strong Sell
Current Market Cap: £61.4B
See more data about GSK stock on TipRanks’ Stock Analysis page.